Results 301 to 310 of about 74,631 (338)
Some of the next articles are maybe not open access.
The American Journal of Nursing, 1974
chronic care facility with no hope of improvement. Parkinsonism is a fairly common, disabling, movement disorder caused by dysfunction of the extrapyramidal system. There are 90 to 110 cases per 100,000 people and an annual incidence of 20 cases per 100,000 people in the United States(1).
openaire +3 more sources
chronic care facility with no hope of improvement. Parkinsonism is a fairly common, disabling, movement disorder caused by dysfunction of the extrapyramidal system. There are 90 to 110 cases per 100,000 people and an annual incidence of 20 cases per 100,000 people in the United States(1).
openaire +3 more sources
Neurology, 1974
We feel it prudent to sound a note of caution about the use of levodopa in patients with known melanomas or with pigmented lesions. Levodopa was administered to three of our patients with Parkinson9s disease and known melanomas or pigmented lesions.
Jerome L. Shupack, Abraham Lieberman
openaire +3 more sources
We feel it prudent to sound a note of caution about the use of levodopa in patients with known melanomas or with pigmented lesions. Levodopa was administered to three of our patients with Parkinson9s disease and known melanomas or pigmented lesions.
Jerome L. Shupack, Abraham Lieberman
openaire +3 more sources
JAMA: The Journal of the American Medical Association, 1979
To the Editor.— Based on personal experience with a single case of Parkinson's disease and malignant melanoma and an incomplete review of the literature, Sober and Wick (240:554, 1978) conclude that levodopa should be administered to patients with Parkinson's disease who have a history of melanoma.
Joseph Fermaglich, Peyton Delaney
openaire +3 more sources
To the Editor.— Based on personal experience with a single case of Parkinson's disease and malignant melanoma and an incomplete review of the literature, Sober and Wick (240:554, 1978) conclude that levodopa should be administered to patients with Parkinson's disease who have a history of melanoma.
Joseph Fermaglich, Peyton Delaney
openaire +3 more sources
Cardiovascular Effects of Levodopa
JAMA: The Journal of the American Medical Association, 1971The patient with Parkinson's disease under treatment with levodopa may be subject to potentially hazardous cardiovascular effects. The most serious side effect of levodopa in patients is ventricular arrhythmia which is unlikely to occur in a subject with normal heart but a risk in patients with myocardial irritability or ischemia.
Thomas L. Whitsett +1 more
openaire +6 more sources
Clinical Neuropharmacology, 2012
To compare bioavailability and pharmacokinetics of single doses of 3 different levodopa formulations given orally in healthy volunteers. Two marketed formulations, standard levodopa/carbidopa, 100/25 mg (LC-100), and dispersible levodopa/benserazide, 100/25 mg (LB-100), were used as reference formulations for a newly developed dispersible microtablet ...
Mats Ehrnebo +7 more
openaire +2 more sources
To compare bioavailability and pharmacokinetics of single doses of 3 different levodopa formulations given orally in healthy volunteers. Two marketed formulations, standard levodopa/carbidopa, 100/25 mg (LC-100), and dispersible levodopa/benserazide, 100/25 mg (LB-100), were used as reference formulations for a newly developed dispersible microtablet ...
Mats Ehrnebo +7 more
openaire +2 more sources
JAMA: The Journal of the American Medical Association, 1972
To the Editor.— Entitled "Psychiatric Side Effects of Levodopa in Man,"1Frederick Goodwin's article inThe Journaldescribed visual hallucinations among the adverse side effects in Parkinsonian patients treated with levodopa. Prior to this, others2-6described psychosis as an occasional adverse side effect of therapy with levodopa.
openaire +3 more sources
To the Editor.— Entitled "Psychiatric Side Effects of Levodopa in Man,"1Frederick Goodwin's article inThe Journaldescribed visual hallucinations among the adverse side effects in Parkinsonian patients treated with levodopa. Prior to this, others2-6described psychosis as an occasional adverse side effect of therapy with levodopa.
openaire +3 more sources
Movement Disorders, 2007
AbstractLevodopa‐induced dyskinesias (LID) are common and difficult to treat. This review focuses on three issues related to LID: clinical features, classification and rating, pathophysiology and pathogenesis, and management. The three primary clinical syndromes are OFF‐period dystonia, peak‐dose dyskinesia, and diphasic dyskinesia. Several other forms
FABBRINI, Giovanni +4 more
openaire +4 more sources
AbstractLevodopa‐induced dyskinesias (LID) are common and difficult to treat. This review focuses on three issues related to LID: clinical features, classification and rating, pathophysiology and pathogenesis, and management. The three primary clinical syndromes are OFF‐period dystonia, peak‐dose dyskinesia, and diphasic dyskinesia. Several other forms
FABBRINI, Giovanni +4 more
openaire +4 more sources
Annals of Internal Medicine, 1980
Excerpt To the editor: The letter of Lejonc and colleagues (1) in the November 1979 issue on a patient who developed flushing and palpitations and, later, elevated pulse rate and blood pressure as ...
openaire +3 more sources
Excerpt To the editor: The letter of Lejonc and colleagues (1) in the November 1979 issue on a patient who developed flushing and palpitations and, later, elevated pulse rate and blood pressure as ...
openaire +3 more sources
The Effect of Levodopa or Levodopa-Carbidopa (Sinemet) on Fracture Healing
Journal of Orthopaedic Trauma, 2006Levodopa (L-dopa) and L-dopa/carbidopa were evaluated to determine their effectiveness in the stimulation of bone healing of fractures at risk for nonunions.Forty-two retired breeder female Sprague-Dawley rats were divided into 2 experimental groups and 1 control. Thirty-six rats were evaluated for results. The right femur of each rat was fractured and
Gregory A. Tayrose +4 more
openaire +3 more sources
The effect of an increased ratio of carbidopa to levodopa on the pharmacokinetics of levodopa
Acta Neurologica Scandinavica, 2009A randomized, cross-over study was designed to compare the effects of an increased ratio (from 1:10 to 1:4) of carbidopa to levodopa on the fate of levodopa and carbidopa in 11 healthy subjects. Four combinations of carbidopa/levodopa (10 mg/100 mg, 25 mg/100 mg, 25 mg/250 mg, 62.5/250 mg) were used.
A Vuorela +4 more
openaire +3 more sources